JP7785669B2 - Ｎ末端ｓｃＦｖ多重特異性結合分子 - Google Patents

Ｎ末端ｓｃＦｖ多重特異性結合分子

Info

Publication number
JP7785669B2
JP7785669B2 JP2022525837A JP2022525837A JP7785669B2 JP 7785669 B2 JP7785669 B2 JP 7785669B2 JP 2022525837 A JP2022525837 A JP 2022525837A JP 2022525837 A JP2022525837 A JP 2022525837A JP 7785669 B2 JP7785669 B2 JP 7785669B2
Authority
JP
Japan
Prior art keywords
mbm
amino acids
domain
length
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553830A (ja
JP2022553830A5 (https=
Inventor
シェン、ヤン
リー、アン－ウィー
ヤン、ヤン
リン、チャ－ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022553830A publication Critical patent/JP2022553830A/ja
Publication of JP2022553830A5 publication Critical patent/JP2022553830A5/ja
Priority to JP2025157633A priority Critical patent/JP2026016376A/ja
Application granted granted Critical
Publication of JP7785669B2 publication Critical patent/JP7785669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022525837A 2019-11-05 2020-11-04 Ｎ末端ｓｃＦｖ多重特異性結合分子 Active JP7785669B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025157633A JP2026016376A (ja) 2019-11-05 2025-09-24 Ｎ末端ｓｃＦｖ多重特異性結合分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930916P 2019-11-05 2019-11-05
US62/930,916 2019-11-05
PCT/US2020/058798 WO2021091953A1 (en) 2019-11-05 2020-11-04 N-terminal scfv multispecific binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025157633A Division JP2026016376A (ja) 2019-11-05 2025-09-24 Ｎ末端ｓｃＦｖ多重特異性結合分子

Publications (3)

Publication Number Publication Date
JP2022553830A JP2022553830A (ja) 2022-12-26
JP2022553830A5 JP2022553830A5 (https=) 2023-11-13
JP7785669B2 true JP7785669B2 (ja) 2025-12-15

Family

ID=73598993

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525837A Active JP7785669B2 (ja) 2019-11-05 2020-11-04 Ｎ末端ｓｃＦｖ多重特異性結合分子
JP2025157633A Pending JP2026016376A (ja) 2019-11-05 2025-09-24 Ｎ末端ｓｃＦｖ多重特異性結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025157633A Pending JP2026016376A (ja) 2019-11-05 2025-09-24 Ｎ末端ｓｃＦｖ多重特異性結合分子

Country Status (12)

Country Link
US (3) US12240907B2 (https=)
EP (1) EP4054646A1 (https=)
JP (2) JP7785669B2 (https=)
KR (1) KR20220093363A (https=)
CN (1) CN114786730A (https=)
AU (1) AU2020379735A1 (https=)
BR (1) BR112022008552A2 (https=)
CA (1) CA3157075A1 (https=)
IL (1) IL292698A (https=)
MX (1) MX2022005330A (https=)
TW (1) TW202134277A (https=)
WO (1) WO2021091953A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005330A (es) * 2019-11-05 2022-05-26 Regeneron Pharma Moleculas de union multiespecificas con scfv en el extremo nterminal.
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
CN114716548B (zh) * 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
CA3219609A1 (en) * 2021-05-04 2022-11-10 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
KR20250148746A (ko) * 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
WO2025088587A1 (en) * 2023-10-27 2025-05-01 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2025240335A1 (en) * 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521759A (ja) 2009-03-25 2012-09-20 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ３抗体およびこれを用いた方法
JP2016525551A (ja) 2013-07-25 2016-08-25 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US20170174769A1 (en) 2014-03-25 2017-06-22 Regeneron Pharmaceuticals, Inc. FGF21 Receptor Agonists And Uses Thereof
JP2018520987A (ja) 2015-04-29 2018-08-02 インスティテュート フォー リサーチ イン バイオメディシン 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
WO2019005640A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME
JP2019525738A (ja) 2016-06-14 2019-09-12 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
BRPI0820229A2 (pt) 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
AU2010254013A1 (en) 2009-05-28 2011-11-24 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9337942B2 (en) 2009-12-07 2016-05-10 Ntt Docomo, Inc. Propagation path estimation method and program and apparatus using the same
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
SG192673A1 (en) * 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
EA030462B1 (ru) * 2011-05-16 2018-08-31 Дженентек, Инк. Агонисты fgfr1 и способы их применения
UY34542A (es) 2011-12-23 2013-07-31 Mersana Therapeutics Inc ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
EP3107565A4 (en) 2014-02-21 2017-08-23 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
IL296285A (en) * 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
KR20260018979A (ko) 2016-02-05 2026-02-09 젠맵 에이/에스 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
CA3020633A1 (en) 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019005552A (es) 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
DK3635009T3 (da) * 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
KR102871690B1 (ko) * 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
MX2022005330A (es) 2019-11-05 2022-05-26 Regeneron Pharma Moleculas de union multiespecificas con scfv en el extremo nterminal.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521759A (ja) 2009-03-25 2012-09-20 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ３抗体およびこれを用いた方法
JP2016525551A (ja) 2013-07-25 2016-08-25 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
US20170174769A1 (en) 2014-03-25 2017-06-22 Regeneron Pharmaceuticals, Inc. FGF21 Receptor Agonists And Uses Thereof
JP2018520987A (ja) 2015-04-29 2018-08-02 インスティテュート フォー リサーチ イン バイオメディシン 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
JP2019525738A (ja) 2016-06-14 2019-09-12 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
WO2019005640A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bart E.C.G. DE GOEIJ et al.，Molecular Cancer Therapeutics，2016年，15(11)，pp. 2688-2697
Rachel M. DEVAY et al.，Bioconjugate Chemistry，2017年，Vol. 28，pp. 1102-1114
Xiufeng WU et al.，Methods，2018年08月30日，Vol. 154，pp. 3-9

Also Published As

Publication number Publication date
AU2020379735A1 (en) 2022-05-26
JP2026016376A (ja) 2026-02-03
EP4054646A1 (en) 2022-09-14
US20210130477A1 (en) 2021-05-06
BR112022008552A2 (pt) 2022-08-09
MX2022005330A (es) 2022-05-26
JP2022553830A (ja) 2022-12-26
US12240908B2 (en) 2025-03-04
TW202134277A (zh) 2021-09-16
US20220251220A1 (en) 2022-08-11
KR20220093363A (ko) 2022-07-05
IL292698A (en) 2022-07-01
US20250171545A1 (en) 2025-05-29
WO2021091953A1 (en) 2021-05-14
CN114786730A (zh) 2022-07-22
US12240907B2 (en) 2025-03-04
CA3157075A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
JP7785669B2 (ja) Ｎ末端ｓｃＦｖ多重特異性結合分子
US20240247069A1 (en) Fgfr3 binding molecules and methods of use thereof
US20240383990A1 (en) Hinge-modified bispecific antibodies
JP2025026957A (ja) ＩＬ－１β受容体シグナル伝達に干渉する剤
US20220372168A1 (en) Multispecific fgf21 receptor agonists and their uses
TW202506728A (zh) 活化素a受體樣1型(alk1)之雙特異性促效性抗體
CN117597365A (zh) 多特异性fgf21受体激动剂及其应用
US20250011449A1 (en) Circularized antibody molecules
WO2025240335A1 (en) Fgfr3 binding molecules and methods of use thereof
WO2026044000A1 (en) Multispecific antibodies and methods of use thereof
KR20260013458A (ko) Il12 수용체에 대한 이중특이적 효현성 항체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251203

R150 Certificate of patent or registration of utility model

Ref document number: 7785669

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150